The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

The HPV vaccine, Gardasil, has gained approval for additional indications from China's National Medical Products ...

Merck's Gardasil vaccine, previously only available to women, has now been approved for men in China. This approval may help ...

In 2022, over 500 plaintiffs filed a case alleging that Merck Sharp & Dohme Corp., a drug manufacturing company, failed to ...

The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced has approved the medicine sotatercept, Winrevair, to ...

MSD's new drug combination shows promise in HIV-1 treatment, aiming to offset potential losses from Keytruda's patent ...

Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...

Merck Sharp & Dohme is in dispute with Clonmel Healthcare and, separately, Teva Finland over SPC rights for different combination products before those national courts. First, having confirmed the ...

Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...